Anebulo Pharmaceuticals (ANEB)

Executive Summary

Anebulo Pharmaceuticals is a clinical-stage biotech company focused on developing ANEB-001, a cannabinoid receptor antagonist for acute cannabis intoxication and substance use disorders. With rising cannabis legalization and related emergency visits, ANEB-001 addresses an urgent medical need. The company is currently in Phase 3 trials, aiming to provide the first FDA-approved treatment for cannabis poisoning. Anebulo's platform leverages its expertise in cannabinoid modulation, positioning it to capture a significant market as cannabis use grows. The company was founded in 2019 and is headquartered in Austin, Texas.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data for ANEB-001 in Acute Cannabis Intoxication55% success
• Q2 2027FDA Meeting or Guidance for NDA Submission40% success
• TBDStrategic Partnership or Licensing Deal30% success